A pioneer in novel therapies for airway repair has agreed to team up with an expert in respiratory disease treatment to fight a common foe: chronic obstructive pulmonary disease (COPD), the German-based company Boehringer Ingelheim announced recently.
The agreement reunites Boehringer, known for its respiratory work, with New
York-based Weill Cornell Medicine. The companies had previously worked together on
inflammatory bowel disease (IBD), and their goal now is to find ways to curb — and possibly reverse — the
progression of COPD.
COPD is one of the chronic lower respiratory diseases that together are
leading cause of death in the United States. Approximately 15
million Americans have been diagnosed with COPD. While there is no cure,
COPD researchers continue to work to keep sufferers active and enjoying
a high quality
Lead investigator Dr. Ronald Crystal, Weill Cornell’s chairman
of genetic medicine, said the two firms have already looked into
“We will look to further expand our
knowledge about progressive airway destruction … and focus on promising
therapeutic concepts with the potential to slow down or halt progressive
airway damage in patients with COPD,” Crystal said.
Partnership spurs efforts against COPD
Organizations in this Story
Want to get notified whenever we write about Boehringer-Ingelheim ?
Next time we write about Boehringer-Ingelheim, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts